Hospital

Two Houston Methodist cancer researchers were granted a quarter-million dollars each to study some of the most lethal forms cancer, including triple-negative breast cancer and multiple myeloma.

Vaccines reduce the risk of COVID-19 infection and hospitalization, but a recent study suggests that misinformation could make adults hesitant to vaccinate children 5 to 11 years of age.

A large collective of researchers may be one step closer to developing a vaccine against HIV after engineering a protein that triggers a widespread antibody response.

Women with a history of gestational diabetes had a 45% increased risk of overall cardiovascular and cerebrovascular diseases.

Lisa Schwartz, PharmD, RPh, senior director of Professional Affairs at NCPA, discusses the Drug Supply Chain Security Act and why it was updated for the distribution of naloxone.

Currently available agents may reduce the need for stem cell transplantation in patients with acute lymphocytic leukemia.

Relapses remain a challenge in treating patients with leukemia.

Loosened restrictions will likely create a more pronounced influenza season this fall.

Respiratory infections have been associated with onset of type 1 diabetes in previous research, but this risk was notably higher among those with COVID-19 in this study.

The FDA approved the only companion diagnostic that is indicated to assess low levels of HER2 proteins in patients with metastatic breast cancer.

Kurt Proctor, PhD, RPh, senior vice president of strategic initiatives at NCPA, discussed the importance of continue education for pharmacists.

Understanding long-term frailty trajectories with kidney function measures could help prevent worse adverse health outcomes in older patients.

Bulevirtide is a synthetic myristoylated peptide derived from the pre-S1 domain of the hepatitis B virus large surface protein.

Two recent clinical trials highlight the novel therapy options available to patients in the upfront and relapsed settings.

An integrative efficacy score would incorporate the depth, duration, and prevalence of tumor response.

Mosunetuzumab showed promising results in complete response rate in patients with follicular lymphoma.

Futibatinib (Lytgobi, Taiho Oncology, Inc) is indicated for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

Women Pharmacist Day takes place October 12th, 2022.

Study results show that intravenous immunoglobulin therapy can help combat this type of PRCA in individuals with anemia.

As individuals in a society, all people have implicit, or unconscious, beliefs that they have been socialized to hold; however, health care professionals’ implicit biases can impact patients’ lives.

Pharmacy Times will be spotlighting pharmacists throughout the month of October to recognize their contributions to the health care field.

Phoenix-area Walgreens pharmacist Matthew Pruitt earns top honor as 2022 Pharmacist of the Year.

Biology and disease type may help determine which therapeutic options could work best for patients with Waldenstrom macroglobulinemia.

Empagliflozin has been found to lower the risk of death due to cardiovascular events and the number of first and recurrent heart failure hospitalizations.

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

All of the findings indicate that inadequate margin widths result in higher risks of distant recurrence and breast cancer mortality, as well as increased total recurrence.

Ivosidenib plus azacitidine shows benefits in event-free survival, overall survival, and clinical responses compared with placebo in patients with IDH1-mutated acute myeloid leukemia.

The functional and physical well-being and other scores from the survey are more favorable for those who were treated with the therapy, investigators say.

A researcher discusses how developing tertiary lymphoid structures may reach a greater maturity level within the tumor microenvironment.